Foamix to Present Corporate Overview at the Rodman & Renshaw 18th Annual Global Investment Conference
Title: Rodman & Renshaw 18th Annual
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including
For more information, please visit www.foamixpharma.com.
Dorit Hayon, BD Foamix Pharmaceuticals Ltd.+972-8-9316233 IR@foamixpharma.com US Investor Relations Michael Rice LifeSci Advisors, LLC646-597-6979 firstname.lastname@example.org